Nuwellis Inc vs Teucrium Soybean Fund — how do they compare? Nuwellis Inc trades at $1.41 (market cap $542.80K), while Teucrium Soybean Fund trades at $25.05. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | SOYB | |
|---|---|---|
Market Cap | $542.80K | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $220.50 | $26.28 |
52-Week Low | $1.42 | $21.46 |
Enterprise Value | -$1.27M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.41, down 0.7% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with preliminary Q2 2026 revenue up 14% year-over-year, but remains unprofitable with a net income margin of -217.22%. Recent developments include a reverse stock split, new CEO appointment, and expansion of its Aquadex platform into new pediatric markets. Cash flow from operations is negative, though recent financing activities have provided capital.
The outlook is mixed: growth initiatives and analyst support offer potential, but persistent losses and high cash burn pose significant risks. Investors should weigh the company's expansion against its financial sustainability.
SOYB trades at $25.05, down 0.48% on the day, with a bearish technical bias from moving averages and neutral oscillators. Key support and resistance cluster at $25. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights agricultural sector volatility from geopolitical tensions and trade developments.
The outlook is clouded by missing financial data, though China's $17 billion U.S. crop purchase pledge through 2028 (Zacks Investment Research, 2026-05-18) offers potential tailwinds. Risks include commodity price swings from Middle East conflicts (24/7 Wall Street, 2026-07-24) and opaque company performance.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →